It may take long time to achieve the goal but indicators showing volume moving better
InspireMD, Inc. is a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease.
Now like you and many others I'm shocked by NSPR price action, so what could have caused it? Well theres one and that was the FDA IDE approval, yet today was ann that they got the full FDA IDE approval green light.
-Got FDA IDE approval in the US today
-Last week they where at LD Micro 500 they gave us some company insights
1: Theres already sales in Brazil...
Okay I'm gonna start off with the news
-NSPR beat earnings by 44%, yet still losing money. It has been making more money due to its past performance and not losing as much. We can project that they might be profitable next year.
-Their offering that was held in June came out that it was so they can remain compliant with the exchange. That Friday they have...
Well seems like we continue the sell off of the Brazil news that I didn't sell. So what news is there to push it higher? Well if ER repeats the same pattern we can suspect them beating EPS and and Beating Revenue.
-Earnings this wednesday, a week early
-They are hitting their road map this year...
Now buying my 3000 shares than seeing it pump to .61 (highest RH showed), was just luck with getting the news about Brazil approval NSPR product, yet looking at the chart begs to wonder is it over?
-CGuard got approval to be used in Brazil. I will post a DD at the end of this for NSPR, yet the consumer market of CGuard in Brazil can be up too 213 million...
The market atm is pretty boring. Bitcoin is doing nothing, stocks trading on news, Tesla mooning on earnings epectations with possibility of NASDAQ listing, cruise lines crap, and tech stocks booming. Now I been watching NSPR a little trying to find a good time to buy. NSPR is a medical stock that helps certain surgeries possible, yet its downfall is its not sold...
- Product: CGuard with MicroNET for Stroke Prevention
- Stroke is 2nd Leading Cause of Death Worldwide (WHO)
- Currently Sold in 39 Countries
- Expanding to Brazil, China, and Japan
- CE Mark -- FDA Approval Ongoing
- 14 USA, 33 World Patents
- 7 Successful Clinical Trials, 4 On-going
- Becoming the New Standard of Care
- Minimally Invasive Outpatient Procedure
If you seen any of my other basic charts, you know I like wedges. Here I see another forming for NSPR. I don't always play these for mega pumps. I see this one eventually going to fill that GAP up north.
I've been having some success with wedges, from my published ideas, 1 played out and 1 was a dud, 1 still to be seen? Either way I like wedges.
I wrote an extensive piece on NSPR in which I go into depth on the company and the potential turnaround story, you can find it here: rockvuecapital.wordpress.com
Trading at a 77% discount to book value, an 81% discount to sales, an 81% discount to NCAV, and a 43% discount to net cash, NSPR is roadkill in the...
The market is not ready to take this higher. Strong Resistance at $.80 which indicates there are no buyers at this level(or above). High volume is a good indicator. Will need consecutive days of higher volume (and higher prices) to confirm bullish price action.
NSPR is trading in the middle of a rising wedge, so it has possibilities to trade long if the lower channel holds or to go short if you see a rejection on the upper channel. A strong rejection on the upper channel can determine a breakout to the downside.